The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict NuVasive's revenues will expand 3.7% and EPS will grow 10.0%.
The average estimate for revenue is $157.3 million. On the bottom line, the average EPS estimate is $0.22.
Last quarter, NuVasive booked revenue of $165.8 million. GAAP reported sales were 10% higher than the prior-year quarter's $150.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.34. GAAP EPS were -$0.06 for Q4 versus -$0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 74.5%, 80 basis points worse than the prior-year quarter. Operating margin was 8.4%, 180 basis points better than the prior-year quarter. Net margin was -1.7%, 500 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $656.0 million. The average EPS estimate is $1.00.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 168 members out of 187 rating the stock outperform, and 19 members rating it underperform. Among 38 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 34 give NuVasive a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on NuVasive is outperform, with an average price target of $19.56.
Is NuVasive the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add NuVasive to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's What Pressured NuVasive, Inc. Stock Today
NuVasive went out of its way to present some mixed results.
5 Supernova Stocks That Have Flown Under the Radar: NuVasive
Among the 210 stocks David Gardner has on his active recommendation list, not all get the recognition they deserve in the markets.
Why Akamai Technologies, NuVasive, and MacroGenics Jumped Today
Even though the market slumped, these stocks gained ground. Find out why.